CSCI(Delisted)
Cosciens BiopharmaยทNASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CSCI
Cosciens Biopharma Inc.
A specialty biopharmaceutical company that develops and commercializing a diversified portfolio of pharmaceutical and diagnostic products
c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7
--
Cosciens Biopharma Inc., was established on September 12, 1990 under the Canada Business Corporations Act and continues to be managed by it. Aeterna Zentaris is a specialty biopharmaceutical company that commercializes and develops therapeutic and diagnostic tests. The company's product line includes compounds in all stages from development to sale. The company's main business strategy is to make progress together with strategic partners, and its key product candidates on the product development line are mainly used in the fields of oncology and endocrinology. In addition, the company has continued to advance other clinical and preclinical procedures, some of which have been authorized by different government agencies. The company's vision is to become an integrated professional biopharmaceutical company.
Company Financials
EPS
CSCI has released its 2025 Q2 earnings. EPS was reported at -0.85, versus the expected 0, missing expectations. The chart below visualizes how CSCI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CSCI has released its 2025 Q2 earnings report, with revenue of 2.75M, reflecting a YoY change of 17.63%, and net profit of -2.70M, showing a YoY change of -89.94%. The Sankey diagram below clearly presents CSCI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
